These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 27928801

  • 1. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
    Dong Z, Gao J, Gong J, Li J, Li Y, Wang X, Li Y, Shen L, Li J.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov 25; 19(11):1286-1289. PubMed ID: 27928801
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Two-year adjuvant imatinib mesylate after complete resection of localized, high-risk GIST with KIT exon 11 mutation.
    Kang YK, Kang BW, Im SA, Lee JL, Park SR, Kang WK, Chang HM, Kim TW, Oh DY, Jung KH, Ryu MH.
    Cancer Chemother Pharmacol; 2013 Jan 25; 71(1):43-51. PubMed ID: 23053257
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy observation on imatinib adjuvant therapy with longer duration in patients with gastrointestinal stromal at intermediate or high risk of recurrence].
    Li J, Dang YZ, Gao J, Shen L.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar 25; 16(3):216-20. PubMed ID: 23536338
    [Abstract] [Full Text] [Related]

  • 5. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
    Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P.
    JAMA; 2012 Mar 28; 307(12):1265-72. PubMed ID: 22453568
    [Abstract] [Full Text] [Related]

  • 6. [Analysis of imatinib trough concentration at steady state in adjuvant therapy of patients with high risk gastrointestinal stromal tumor].
    Wan WZ, Zhang P, Zeng XY, Zhou H, Lin Y, Xiong Z, Zhang RZ, Liu WZ, Han Y, Tao KX.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Sep 25; 22(9):848-855. PubMed ID: 31550824
    [Abstract] [Full Text] [Related]

  • 7. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
    Rutkowski P, Ziętek M, Cybulska-Stopa B, Streb J, Głuszek S, Jankowski M, Łopacka-Szatan K, Las-Jankowska M, Hudziec P, Klimczak A, Olesiński T, Świtaj T, Koseła-Paterczyk H, Bylina E, Osuch C.
    Eur J Surg Oncol; 2021 May 25; 47(5):1191-1195. PubMed ID: 32826113
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP.
    JAMA Oncol; 2018 Dec 01; 4(12):e184060. PubMed ID: 30383140
    [Abstract] [Full Text] [Related]

  • 9. The outcome of targeted therapy in advanced gastrointestinal stromal tumors (GIST) with non-exon 11 KIT mutations.
    Osuch C, Rutkowski P, Brzuszkiewicz K, Bylina E, Limon J, Siedlecki JA.
    Pol Przegl Chir; 2014 Jul 01; 86(7):325-32. PubMed ID: 25222580
    [Abstract] [Full Text] [Related]

  • 10. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
    Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP.
    J Clin Oncol; 2014 May 20; 32(15):1563-70. PubMed ID: 24638003
    [Abstract] [Full Text] [Related]

  • 11. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
    Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P.
    JAMA Oncol; 2017 May 01; 3(5):602-609. PubMed ID: 28334365
    [Abstract] [Full Text] [Related]

  • 12. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK.
    J Manag Care Pharm; 2010 Sep 01; 16(7):482-91. PubMed ID: 20726677
    [Abstract] [Full Text] [Related]

  • 13. [Changes of diagnosis and treatment for gastrointestinal stromal tumors during a 18-year period in four medical centers of China].
    Qiu H, Zhang P, Feng X, Chen T, Sun X, Yu J, Chen Z, Li Y, Tao K, Li G, Zhou Z.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov 25; 19(11):1265-1270. PubMed ID: 27928797
    [Abstract] [Full Text] [Related]

  • 14. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
    Kang HJ, Ryu MH, Kim KM, Park YS, Choi J, Ryoo BY, Kim WH, Im SA, Bang YJ, Park SH, Lee JH, Chung IJ, Bae HI, Kim JG, Lee KH, Song HS, Kwon HC, Baek JH, Shin DB, Lee KE, Kang YK.
    Acta Oncol; 2012 Apr 25; 51(4):528-36. PubMed ID: 22150077
    [Abstract] [Full Text] [Related]

  • 15. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
    Zhang L, Cai M, Deng J, Wang X, Wang B, Liu N, Pan Y, Zhang R, Cui Q, Liang H.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr 25; 17(4):331-4. PubMed ID: 24760639
    [Abstract] [Full Text] [Related]

  • 16. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A, Boglione A.
    Recenti Prog Med; 2015 Jan 25; 106(1):17-22. PubMed ID: 25621775
    [Abstract] [Full Text] [Related]

  • 17. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
    Lin JX, Chen QF, Zheng CH, Li P, Xie JW, Wang JB, Lu J, Chen QY, Cao LL, Lin M, Tu RH, Huang CM.
    J Cancer Res Clin Oncol; 2017 Apr 25; 143(4):727-734. PubMed ID: 28083710
    [Abstract] [Full Text] [Related]

  • 18. Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study.
    Callejo A, Faouzi S, Bouché O, Bertucci F, Chevalier T, Isambert N, Duffaud F, Collard O, Penel N, Terrier P, Mir O, Blay JY, Le Cesne A.
    Target Oncol; 2021 Jul 25; 16(4):485-492. PubMed ID: 34089444
    [Abstract] [Full Text] [Related]

  • 19. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL, Li J, Li J, Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun 25; 41(6):386-90. PubMed ID: 22932406
    [Abstract] [Full Text] [Related]

  • 20. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
    DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.
    Ann Surg; 2013 Sep 25; 258(3):422-9. PubMed ID: 23860199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.